Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report

A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase. Hyper-cyclophosphamide, vincristine...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: Komeno, Yukiko, Uchida, Naoyuki, Satoh, Yumiko, Uryu, Hideki, Iwata, Yuko, Masuda, Akiko, Iihara, Kuniko, Yatomi, Yutaka, Taniguchi, Shuichi, Ryu, Tomiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2017
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5452986/
https://ncbi.nlm.nih.gov/pubmed/28599428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.5989
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak